Phase 2 open-label data for VDPHL01 in women with pattern hair loss showed robust hair growth, rapid onset, and high patient satisfaction, with a favorable safety profile and no serious adverse events. Results support advancement to Phase 2/3 trials and position VDPHL01 as a potential first FDA-app…
Phase 2 open-label data for VDPHL01 in women with pattern hair loss showed robust hair growth, rapid onset, and high patient satisfaction, with a favorable safety profile and no serious adverse events. Results support advancement to Phase 2/3 trials and position VDPHL01 as a potential first FDA-approved oral therapy for this large, underserved population.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
